Phaseline

Targets › F10

F10 (Coagulation factor X): drug programs, companies and trials

55 programs from 47 companies in 81 trials: 38 Phase 4, 26 Phase 3, 9 Phase 2, 8 Phase 1; Cardiovascular, Oncology, Hematology; next expected readout Nov 2026.

Factor Xa is a vitamin K-dependent glycoprotein that converts prothrombin to thrombin in the presence of factor Va, calcium and phospholipid during blood clotting. Factor Xa activates pro-inflammatory signaling pathways in a protease-activated receptor (PAR)-dependent manner. (UniProt, P00742)

Open in Phaseline: the race on F10, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
RocheEmicizumab
Coagulation factor IX and X other
F9, F10Phase 4Severe Hemophilia A; Von Willebrand Disease, Type 3; Factor VIII Deficiency, Congenital; Hemophilia A Patient …Nov 2026
Hospital Sirio-LibanesEdoxaban
Coagulation factor X inhibitor
F10Phase 4Atrium; FibrillationDec 2026
Ottawa Hospital Research InstituteRivaroxaban
Coagulation factor X inhibitor
F10Phase 4Atrial Fibrillation; Venous Thromboembolism; SVTDec 2026
China National Center for Cardiovascular DiseasesRivaroxaban
Coagulation factor X inhibitor
F10Phase 4Coronary Artery Disease; Atrial FibrillationDec 2026
Assistance Publique - Hôpitaux de ParisApixaban
Coagulation factor X inhibitor
F10Phase 4Stroke; Intrahepatic Non Cirrhotic Portal HypertensionDec 2026
Herlev and Gentofte HospitalApixaban
Coagulation factor X inhibitor
F10Phase 4Deep Vein Thrombosis; Atrial FibrillationMar 2027
Herlev and Gentofte HospitalEdoxaban
Coagulation factor X inhibitor
F10Phase 4Deep Vein Thrombosis; Atrial FibrillationMar 2027
Herlev and Gentofte HospitalRivaroxaban
Coagulation factor X inhibitor
F10Phase 4Deep Vein Thrombosis; Atrial FibrillationMar 2027
Asian Institute Of Medical SciencesApixaban
Coagulation factor X inhibitor
F10Phase 4CirrhosisApr 2027
Children's Hospital of Fudan UniversityRivaroxaban
Coagulation factor X inhibitor
F10Phase 4Kawasaki DiseaseJun 2027
Population Health Research InstituteApixaban
Coagulation factor X inhibitor
F10Phase 4Stroke; Bleeding Post Cardiac SurgeryJun 2027
Population Health Research InstituteEdoxaban
Coagulation factor X inhibitor
F10Phase 4Stroke; Bleeding Post Cardiac SurgeryJun 2027
Population Health Research InstituteRivaroxaban
Coagulation factor X inhibitor
F10Phase 4Stroke; Bleeding Post Cardiac SurgeryJun 2027
Imperial College LondonApixaban
Coagulation factor X inhibitor
F10Phase 4Venous ThromboembolismJun 2027
Korea University Anam HospitalRivaroxaban
Coagulation factor X inhibitor
F10Phase 4Atrial FibrillationJun 2027
Kiranya ArnoldApixaban
Coagulation factor X inhibitor
F10Phase 4Venous ThromboembolismSep 2027
The University of The West IndiesApixaban
Coagulation factor X inhibitor
F10Phase 4Coronary Artery DiseaseOct 2027
Chinese Academy of Medical Sciences, Fuwai HospitalRivaroxaban
Coagulation factor X inhibitor
F10Phase 4Mitral RegurgitationOct 2027
University of BirminghamApixaban
Coagulation factor X inhibitor
F10Phase 4Atrial Fibrillation; ThromboprophylaxisDec 2027
Ottawa Hospital Research InstituteApixaban
Coagulation factor X inhibitor
F10Phase 4Atrial Fibrillation; Venous ThromboembolismDec 2027
Karolinska InstitutetApixaban
Coagulation factor X inhibitor
F10Phase 4Left Ventricular ThrombusApr 2028
Clinical Urology and Epidemiology Working GroupApixaban
Coagulation factor X inhibitor
F10Phase 4Venous ThromboembolismSep 2028
Yonsei UniversityApixaban
Coagulation factor X inhibitor
F10Phase 4Atrial Fibrillation Patients With Moderate or High Stroke Risk Who Had Undergone Catheter Ablation of Atrial Fibrillation; StrokeOct 2028
Vastra Gotaland RegionApixaban
Coagulation factor X inhibitor
F10Phase 4Takotsubo SyndromeDec 2028
Samsung Medical CenterEdoxaban
Coagulation factor X inhibitor
F10Phase 4Atrial Fibrillation (AF)Jun 2031
VA Office of Research and DevelopmentApixaban
Coagulation factor X inhibitor
F10Phase 4Atrial FibrillationOct 2032
Mansoura UniversityApixaban
Coagulation factor X inhibitor
F10Phase 4Cirrhosis–
Children's Hospital Los AngelesFeiba
Activated prothrombin complex concentrate (aPCC) - contains vitamin K-dependent clotting f
F2, F7, F10Phase 4Hemophilia A With Inhibitor–
Yale UniversityApixaban
Coagulation factor X inhibitor
F10Phase 3Intracerebral HemorrhageApr 2027
University Hospital, BrestApixaban
Coagulation factor X inhibitor
F10Phase 3Polycythemia VeraJul 2027
Region StockholmApixaban
Coagulation factor X inhibitor
F10Phase 3Chronic Kidney DiseasesDec 2027
Walton Centre NHS Foundation TrustApixaban
Coagulation factor X inhibitor
F10Phase 3Traumatic Intracranial HaemorrhageDec 2027
University of ArizonaApixaban
Coagulation factor X inhibitor
F10Phase 3Left Ventricular ThrombusJul 2028
TakedaTAK-330
Factor Xa inhibitor reversal agent (recombinant human Factor Xa)
F10Phase 3Coagulation DisorderAug 2028
Queen Mary University of LondonApixaban
Coagulation factor X inhibitor
F10Phase 3ThrombosisAug 2028
Texas Cardiac Arrhythmia Research Foundationapixaban
Coagulation factor X inhibitor
F10Phase 3Atrial Fibrillation (AF)Dec 2028
University Hospital, LilleApixaban
Coagulation factor X inhibitor
F10Phase 3Intracerebral HemorrhageJan 2029
VarmXReltodecacog alfa (VMX-C001)
Factor X (prothrombin complex) analog
F10Phase 3Blood Loss, SurgicalJan 2029
Columbia UniversityApixaban
Coagulation factor X inhibitor
F10Phase 3LVAD (Left Ventricular Assist Device) ThrombosisAug 2029
Sunnybrook Health Sciences CentreEdoxaban
Coagulation factor X inhibitor
F10Phase 3Stroke, IschemicDec 2031
University of VermontApixaban
Coagulation factor X inhibitor
F10Phase 3CancerAug 2035
Icahn School of Medicine at Mount SinaiApixaban
Coagulation factor X inhibitor
F10Phase 3Atrial Fibrillation–
National Institute of Cardiovascular Diseases, PakistanApixaban
Coagulation factor X inhibitor
F10Phase 3Acute Myocardial Infarction of Anterior Wall–
Icahn School of Medicine at Mount SinaiEdoxaban
Coagulation factor X inhibitor
F10Phase 3Atrial Fibrillation–
Icahn School of Medicine at Mount SinaiOral Anticoagulant (OAC) - Vitamin K Antagonist (VKA) or Direct Oral Anticoagula
Vitamin K antagonist or factor Xa/IIa inhibitor anticoagulation
F2, F7, F9, F10Phase 3Atrial Fibrillation–
University of Vermont Medical CenterApixaban
Coagulation factor X inhibitor
F10Phase 2GlioblastomaDec 2026
Centre Hospitalier Universitaire Dijonapixaban
Coagulation factor X inhibitor
F10Phase 2Prolonged AnticoagulationAug 2028
Northwell HealthFEIBA
Factor VIII inhibitor bypass activity - prothrombin complex concentrate containing factors
F2, F7, F9, F10Phase 2Cardiac DiseaseNov 2028
Centre Hospitalier Universitaire VaudoisApixaban
Coagulation factor X inhibitor
F10Phase 2Liver Cirrhosis–
Centre Hospitalier Universitaire VaudoisEdoxaban
Coagulation factor X inhibitor
F10Phase 2Liver Cirrhosis–
Insel Gruppe AG, University Hospital BernApixaban
Coagulation factor X inhibitor
F10Phase 1Liver CirrhosisDec 2026
BayerBAY3389934
Factor IIa (thrombin) and Factor Xa inhibitor
F2, F10Phase 1Sepsis; Drug-drug InteractionDec 2026
Hyewon ChungEdoxaban
Coagulation factor X inhibitor
F10Phase 1Healthy–
Shaanxi Micot Pharmaceutical TechnologyMT1011
Factor IIa and Factor Xa inhibitor reversal agent
F2, F10Phase 1Used in Patients Receiving Anticoagulant Therapy (e.g., Rivaroxaban or Apixaban, Inhibitors of Coagulation Factor Xa) Who Require Reversal of Anticoagulation–
Thomas Jefferson UniversityRivaroxaban
Coagulation factor X inhibitor
F10Phase 1Postpartum–

Conditions

Atrial Fibrillation (13) Venous Thromboembolism (6) Stroke (5) Deep Vein Thrombosis (3) Liver Cirrhosis (3) Bleeding Post Cardiac Surgery (3) Intracerebral Hemorrhage (2) Atrial Fibrillation (AF) (2) Left Ventricular Thrombus (2) Coronary Artery Disease (2) Postpartum (2) Severe Hemophilia A (2)

Modalities

small molecule (52), mixed (2)

Companies

Herlev and Gentofte Hospital (3) Population Health Research Institute (3) Icahn School of Medicine at Mount Sinai (3) Ottawa Hospital Research Institute (2) Centre Hospitalier Universitaire Vaudois (2) University Hospital, Lille (1) Texas Cardiac Arrhythmia Research Foundation (1) Karolinska Institutet (1) Imperial College London (1) China National Center for Cardiovascular Diseases (1) Thomas Jefferson University (1) Queen Mary University of London (1) Roche (1) Clinical Urology and Epidemiology Working Group (1) The University of The West Indies (1) Kiranya Arnold (1) Centre Hospitalier Universitaire Dijon (1) Takeda (1) Insel Gruppe AG, University Hospital Bern (1) Yale University (1)

Related targets

F2 (5) F9 (3) F7 (3)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.